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ABSTRACT
Objective: To estimate the impact of achieving
alternative average population alcohol consumption
levels on chronic disease mortality in England.
Design: A macro-simulation model was built to
simultaneously estimate the number of deaths from
coronary heart disease, stroke, hypertensive disease,
diabetes, liver cirrhosis, epilepsy and ﬁve cancers that
would be averted or delayed annually as a result of
changes in alcohol consumption among English
adults. Counterfactual scenarios assessed the impact
on alcohol-related mortalities of changing (1) the
median alcohol consumption of drinkers and (2) the
percentage of non-drinkers.
Data sources: Risk relationships were drawn from
published meta-analyses. Age- and sex-speciﬁc
distributions of alcohol consumption (grams per day)
for the English population in 2006 were drawn from
the General Household Survey 2006, and age-, sex-
and cause-speciﬁc mortality data for 2006 were
provided by the Ofﬁce for National Statistics.
Results: The optimum median consumption level for
drinkers in the model was 5 g/day (about half a unit),
which would avert or delay 4579 (2544 to 6590)
deaths per year. Approximately equal numbers of
deaths from cancers and liver disease would be
delayed or averted (w2800 for each), while there was
a small increase in cardiovascular mortality. The model
showed no beneﬁt in terms of reduced mortality when
the proportion of non-drinkers in the population was
increased.
Conclusions: Current government recommendations
for alcohol consumption are well above the level likely
to minimise chronic disease. Public health targets
should aim for a reduction in population alcohol
consumption in order to reduce chronic disease
mortality.
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ARTICLE SUMMARY
Article focus
- Alcohol consumption is a risk factor for many
chronic diseases, while providing modest protec-
tion from others. Assessments of the impact of
alcohol on individual chronic diseases can
therefore result in contradictory advice about
the level of alcohol consumption that is optimal
for health.
- The UK Government currently recommends that
men should consume no more than three to four
units per day (24e32 g/day of pure alcohol) and
women should drink no more than two to three
units per day (16e24 g/day). However the net
impact of this level of consumption on chronic
disease mortality is unclear.
- The aim of this study was to estimate the impact
of achieving alternative population alcohol
consumption levels on chronic disease mortality
in England.
Key messages
- Results suggest that the optimum population
level of alcohol consumption for minimising
chronic disease mortality in England is just 5 g
(approximately half a unit) per day.
- Current recommendations for alcohol consump-
tion are well above this level and may not be
compatible with optimum protection of public
health. Substantial reductions in recommenda-
tions and in population alcohol consumption
levels would be needed to minimise the chronic
disease burden associated with alcohol
consumption in England.
- Community beliefs in the protective role of
alcohol in cardiovascular disease are widespread;
however, our modelling shows that when
multiple conditions are considered simulta-
neously, the levels of alcohol that would actually
be likely to be associated with reduced risk of
chronic disease are much lower than is generally
accepted or recommended by government.
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Open Access ResearchAlcohol consumption has signiﬁcant impacts on chronic
disease risk.
1e3 In the UK, it has been estimated that
alcohol-related ill-health is responsible for £3.3 billion in
direct costs to the National Health Service annually.
4
The effects of episodes of heavy alcohol consumption
are clearly detrimental to health, for example, increasing
risk from injuries and violence.
5e7 Less is known about
the overall effects of long-term alcohol consumption on
chronic disease risk in the whole population, due to
alcohol consumption at various levels increasing risk for
some chronic disease outcomes (eg, liver cirrhosis and
cancer), yet decreasing risks of others (eg, cardiovascular
disease (CVD) and diabetes).
The World Cancer Research Fund has recommended
that there is no safe level of alcohol consumption in
relation to cancer risk,
8 and Schutze and colleagues
9
report that up to 10% of all cancers in men and 3% in
women in some European countries may be attributable
to alcohol consumption. This has led to calls for public
health messages to encourage abstinence or signiﬁcant
reductions in alcohol consumption.
91 0There is, however,
a substantial body of evidence that suggests that moderate
alcohol consumption protects against other chronic
diseases, including CVD and diabetes, which are respon-
sible for a substantial burden of disease.
11e13
Substantial research has examined the effects of
alcohol consumption on various chronic diseases;
however, there has been little integration of the ﬁndings
across disease outcomes, thereby precluding the devel-
opment of comprehensive and evidence-based recom-
mendations for population alcohol consumption. The
UK government currently recommends that men should
consume no more than three to four units per day (one
unit ¼8 g (10 ml) of pure alcohol, one pint of standard
beer usually contains between two and three units and
a 175 ml glass of wine approximately two units) and
women should drink no more than two to three units
per day.
14 A large proportion of the literature supporting
alcohol policy in the UK, however, appears to focus on
alcohol ‘misuse’, episodes of heavy drinking and the
social consequences of alcohol consumption
14; it is not
clear that there is evidence that the UK Government
recommended that drinking levels offer the maximum
protection for public health.
The aim of this study was to estimate the impact of
achieving alternative population average alcohol
consumption levels on chronic disease mortality in
England. The research question was: what proportion of
non-drinking in the English population and what level of
alcohol consumption among drinkers would result in
the greatest number of chronic disease deaths delayed or
averted in England compared with recent levels?
METHODS
A macro-simulation model was built that assessed the
impact on mortality from chronic disease of changing
the distribution of alcohol consumption (grams per day)
within the population of England. The Preventable Risk
Integrated ModEl for Alcohol (PRIME-Alcohol) esti-
mates the impact of population changes in alcohol
consumption on chronic disease mortality. Developing
the PRIME-Alcohol model involved the following: iden-
tifying chronic diseases associated with alcohol
consumption, identifying the current (baseline) distri-
bution of alcohol consumption and parameterising the
association between alcohol consumption and chronic
disease.
Selection of mortality outcomes
The initial list of chronic diseases was generated from
those linked to alcohol consumption in the World
Health Organization Global Burden of Disease ‘Global
Health Risks’ report
15 and the World Cancer Research
Fund Report
8 was used to select site-speciﬁc cancers
associated with alcohol consumption. Excluding those
resulting in small numbers of deaths (fewer than 500
deaths in 2006 in England), 11 chronic diseases were
included as outcomes in the PRIME-Alcohol model,
including ﬁve cancer sites.
The PubMed and Cochrane Databases were searched
for meta-analyses of prospective cohort or caseecontrol
studies that quantiﬁed chronic disease risk for different
levels of alcohol consumption. The relationships
between alcohol consumption were diverse, including
protective effects, linear increases in risk and ‘U’-shaped
or ‘J’-shaped relationships. Where multiple suitable
meta-analyses were available, preference was given to
meta-analyses of cohort studies over caseecontrol studies
and to those using lifetime abstainers as the reference
category. Age- and sex-speciﬁc estimates of risk rela-
tionships and estimates adjusted for potential
confounders were used where available.
ARTICLE SUMMARY
Strengths and limitations of this study
- The study used a detailed modelling approach to synthesise the
best available evidence from meta-analysis of prospective
cohort studies and provide for the ﬁrst time an estimate of the
level of alcohol associated with theoretical minimum risk of
a range of chronic diseases, considering both harmful and
protective effects simultaneously.
- The model is dependent on the meta-analyses selected to
deﬁne the parameters. Results may vary signiﬁcantly in other
contexts with varying levels of disease, alcohol consumption
and other risk factors. Furthermore, results depend on the
quality of the available epidemiological evidence, which
remains contested in some areas.
- The approach used also relies on chronic (average) consump-
tion of alcohol and is not able to take account of to take
account of patterns of drinking (eg, binge drinking). Further-
more, the results are based on the assumption of a steady-
state relationship between alcohol consumption patterns and
RR of disease and cannot estimate the time required between
changes in population alcohol consumption levels occurring
and the achievement of changes in mortality rates.
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Modelling optimal alcohol consumption levels for chronic disease preventionDetails of the chronic disease outcomes and the meta-
analyses that were included in the model
8 11 12 16e18 are
shown in table 1.
Identifying the current (baseline) distribution of alcohol
consumption in England
The General Household Survey (GHS) from 2006
19
provided baseline distributions of alcohol consumption
for adults aged 16 years and over. The GHS is a multi-
purpose survey conducted by the Ofﬁce for National
Statistics in the UK. In 2006, it included 18214 adults
aged 16 years and over (overall response rate 74%). To
establish average weekly alcohol consumption, respon-
dents were asked how often over the last year they drank
alcoholic beverages and the amount usually consumed
on any one day. This information is combined to give an
estimate of the respondent’s weekly alcohol consump-
tion in units of alcohol.
20 For the current analyses, units
of alcohol per week was converted to grams per day and
only participants from England were included
(n¼15616). Non-drinkers and very low alcohol
consumers were removed and analysed as a separate
Table 1 Details of mortality outcomes included in the model
Outcome
(ICD-10 codes)
Total
deaths,
England
2006
Deaths
<75 years,
England
2006, n (%) Meta-analysis details
Nature of risk
relationship
Coronary
Heart Disease
(I20e25)
76806 24364 (31.7) 31 Cohort studies,
11 total 1925106
subjects. Adjusted for up to 18
confounders by study. 23 Studies
adjusted for smoking.
Protective at all levels of
consumption
Stroke (I60e69) 45219 7966 (17.6) 10 Cohort studies,
11 total 723571
subjects. Adjusted for up to 18
confounders by study. 8 Studies
adjusted for smoking.
‘U’ or ‘J’ shaped: protection
only at low-to-moderate
consumption
Hypertensive
disease (I10e15)
3742 995 (26.6) 12 Cohort studies,
16 27603 cases.
Adjusted for age, BMI and up to
5 others by study. 4 Studies
adjusted for smoking.
Doseeresponse increased risk
Diabetes
(E11, E14)
4831 1450 (30.0) 15 Cohort studies,
12 11959 cases
among 369862 subjects. Adjusted
for up to 14 confounders by study.
8 Studies adjusted for smoking.
Protective ‘U’ shaped:
greatest protection at low-
to-moderate consumption
Epilepsy
(G40e41)
932 715 (76.7) 4 Caseecontrol studies,
17 698 cases,
1162 controls. Not adjusted for
smoking. Other adjustments varied
by study.
Doseeresponse increased risk
Liver cirrhosis
(K70, K74)
5783 5137 (88.8) 13 Cohort and caseecontrol
studies,
18 2383 cases among
1469323 subjects. Adjusted for
age and gender plus others by
study. 11 Studies adjusted for
smoking.
Doseeresponse increased risk
Cancer
Liver (C22) 2486 1305 (52.5) WCRF/AICR 6 cohort studies.
8
Adjustment varied by study.
4 adjusted for smoking.
Doseeresponse increased risk
Mouth, larynx,
pharynx (C00e14)
1572 1033 (65.7) WCRF/AICR 2 cohort studies.
8
Adjusted for smoking.
Doseeresponse increased risk
Oesophagus
(C15)
6068 3104 (51.2) WCRF/AICR 20 caseecontrol
studies.
8 Adjustment varied by
study. All adjusted for smoking.
Doseeresponse increased risk
Breast (C50) 10302 5644 (54.8) WCRF/AICR 9 cohort studies.
8
Adjustment varied by study
(including age and reproductive
factors). Not adjusted for smoking.
Doseeresponse increased risk
Colorectum
(C18e20)
12876 5587 (43.4) WCRF/AICR 9 cohort studies.
8
Adjustments varied by study.
6 Adjusted for smoking.
Doseeresponse increased risk
BMI, body mass index.
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Modelling optimal alcohol consumption levels for chronic disease preventioncategory (referred to as non-drinkers henceforth).
Excluding this group, alcohol consumption was shown
to be approximately log-normally distributed.
The three parameters for the baseline distribution of
alcohol consumption derived from the GHS for each of
30 age-sex groups were therefore percentage of non-
drinkers, the mean of ln-transformed alcohol consump-
tion of drinkers and the SD of ln-transformed alcohol
consumption of drinkers. Counterfactual scenarios were
modelled by altering one or more of these parameters.
Parameterising the association between alcohol
consumption and chronic disease
The meta-analyses identiﬁed by the literature search
provided estimates of the RR of different levels of
alcohol consumption on chronic disease (table 1). The
RRs used in the PRIME-Alcohol model are shown in
supplementary table S1. These risks were used in
conjunction with the baseline distribution of alcohol
consumption to attribute risk for chronic disease
throughout the age- and sex-speciﬁc populations. Base-
line age, sex and cause-speciﬁc number of mortalities
(England 2006) were provided by the Ofﬁce for National
Statistics. For each chronic disease and ageesex group,
mortality rates were assigned to each level of alcohol
consumption such that the RRs from the meta-analyses
were maintained and the total risk in the population
produced the recorded number of mortalities. These
mortality rates were then applied to the counterfactual
distributions to calculate the number of deaths that
would be expected under the counterfactual scenario.
An example is provided in supplementary table S2.
Uncertainty analysis
The alcoholechronic disease association parameters
were allowed to vary stochastically according to the
distributions reported in the literature. Five thousand
Monte Carlo iterations were run, and the results were
used to calculate 95% credible intervals around the
estimates. Because of the computing requirements of the
Monte Carlo iterations, credible intervals are only
presented for key results.
Deﬁning the counterfactual scenarios
To assess the number of chronic disease mortalities in
England under different alcohol consumption scenarios,
two counterfactual scenarios were analysed: (1) varying
the median consumption among drinkers while holding
the proportion of non-drinkers and the distribution of
consumption levels constant and (2) varying the
proportion of non-drinkers in the population while
holding the median consumption among drinkers
constant.
In the analysis of the ﬁrst scenario, the percentage of
non-drinkers was kept constant while the amount of
alcohol consumed by drinkers in the population was
varied between 1 and 48 g/day (six units), such that the
ageesex distribution of mean alcohol consumption was
maintained. In the analysis of the second scenario, the
total percentage of non-drinkers in the population was
allowed to vary between 0% and 100% such that the
ageesex distribution of non-drinkers was maintained,
while the amount of alcohol consumed by drinkers
remained constant. The aim of the analyses was to ﬁnd
the median level of average alcohol consumption for
England that would be likely to result in the lowest
number of chronic disease mortalities.
The funding bodies supporting the authors of this
work had no role in the present study.
RESULTS
In 2006, 29% of English adults were non-drinkers
according to the deﬁnitions used here (including those
who consume <1 g/day). Rates of non-drinking varied
substantially by age group and sex (supplementary table
S3). Overall, 20% of men and 36% of women were non-
drinkers. In total, there were 170558 deaths in England
in 2006 from the causes of death considered in this
study.
In the ﬁrst counterfactual scenario, varying the
median population level of alcohol consumption among
current drinkers between 1 and 48 g/day, results showed
that approximately 5 g/day (just over half of one unit)
was the optimal level of alcohol consumption, resulting
in 4579 (2544e6590) deaths delayed or averted (table 2
and ﬁgure 1) or approximately 3% of all deaths from
partially alcohol-related chronic diseases. At this level of
consumption, a small predicted increase in risk of CVD
(843 additional deaths per year, +0.7% from 2006 levels)
is counteracted by large decreases in cancer (2668 fewer
deaths,  8%) and liver disease (2828 fewer deaths,
 49%). At this level of consumption, the vast majority
(90%) of deaths delayed or averted were premature
(before age 75).
In variations of the scenario with lower levels of
median alcohol consumption, the shift of a large
proportion of the population into the non-drinker
category resulted in a modelled increase in deaths from
CVD, which was not offset by reductions in cancer, liver
cirrhosis and other chronic conditions. Above 5 g/day,
the additional protective effect of alcohol on CVD was
not enough to offset the additional risk from cancer,
liver cirrhosis and other chronic conditions. For men
and women aged under 75 years, the optimum level of
consumption was slightly lower than for the whole
population, at 3 g/day, at which level 4381 (3327e5400)
deaths before age 75 would be delayed or averted each
year, a decrease of 8% from 2006 levels.
In the second counterfactual scenario, varying the
proportion of non-drinkers in the whole population, the
model showed a net increase in mortality in all versions
of the scenario for which the modelled rates of non-
drinking exceeded the 2006 levels, up to an additional
3160 ( 436 to 6409) lives lost annually if the entire
population were to abstain from alcohol.
Theoretically, optimal results were achieved when
there were zero non-drinkers in the population (ﬁgure 2
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Modelling optimal alcohol consumption levels for chronic disease preventionand supplementary table S4), which resulted in 4160
(95% credible intervals: 908e6962) chronic disease
deaths averted or delayed compared with 2006 mortality
rates. Although a modelled situation in which the whole
population consumes some alcohol would increase
predicted deaths from cancer by 2771 (credible interval
2443e3898, +8% from 2006 levels) and from liver
cirrhosis by 1265 (1166e1360, +22%), this was more
than offset by averting 7705 (5248e11934,  6%) deaths
from CVD. As the proportion of non-drinkers was
increased in the counterfactual scenarios, the reductions
in mortality were attenuated.
DISCUSSION
The PRIME-Alcohol model effectively demonstrates the
potential impact of population usual alcohol consump-
tion on chronic disease mortality, bringing together
a wide range of risk and protective effects of alcohol,
including the increased risks of many cancers and the
protective effect of low-to-moderate consumption on
CVD. Modelling demonstrated that the optimum popu-
lation median alcohol consumption level appears to be
substantially lower than the currently recommended safe
levels in the current UK public health guidance. Based
on this model, reducing the median population alcohol
consumption among current drinkers to around half
a unit (5 g of alcohol) per day would result in around
4600 fewer deaths annually, primarily due to reductions
in cancers and liver cirrhosis. This level of consumption
would equate to as little as one-quarter of a glass of wine
or one-ﬁfth of a pint of beer per day on average.
The model showed no additional beneﬁt to chronic
disease mortality if the proportion of the population
abstaining from alcohol were to be increased. Results
indicated that increasing the proportion of alcohol
consumers in the population (drinking moderately)
would result in reduced CVD mortality; however, this is
of little practical relevance given that there are safer and
more socially acceptable means of reducing CVD risk,
and there are a number of reasons why it would be
imprudent to encourage current non-drinkers to start
drinking. These include the following: encouraging
abstainers to start drinking while encouraging drinkers
to reduce their alcohol consumption is a mixed message
that may be difﬁcult to communicate and promote and
reducing the number of non-drinkers may have an
adverse impact on non-chronic disease health (eg, acci-
dents and injuries). Furthermore, modelled results show
that while reducing the proportion of non-drinkers
would decrease chronic disease deaths overall, this
would increase the number of premature deaths (before
75 years; see supplementary table 4), increasing the
impact on years of life lost. On this basis, we recommend
that the public health target for alcohol consumption in
England should be to reduce median alcohol
consumption to half a unit per day for both men and
women and to maintain the current level of non-
drinkers within the population. The recommendations
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Modelling optimal alcohol consumption levels for chronic disease preventionand public messages around restriction of alcohol
consumption that would be required to achieve this
target median level of consumption are beyond the
scope of this work but should take account of the likely
impacts on chronic disease as modelled here, as well as
aiming to reduce other known risks and address patterns
of consumption.
Public health behavioural recommendations should
ideally be based on the best available evidence for opti-
mising population health outcomes. In practice, public
health goals in the UK have often been based on
a mixture of evidence of health risks and pragmatic
considerations about setting a goal that is considered
achievable. A counterfactual modelling analysis such as
the type reported in this paper is particularly useful for
setting public health goals, as its ﬂexibility can provide
predicted impacts for a range of counterfactual
scenarios, which can then inform policy makers both of
the optimum goal and the strength of any pragmatic
goal that they may consider.
A limitation of the PRIME-Alcohol model is that it is
based on usual average levels of alcohol consumption
and is unable to take account of patterns of drinking (eg,
binge drinking) or provide any evidence about the least
harmful pattern of alcohol consumption. There is
evidence that patterns of drinking play an important role
in disease risk
21 and particularly in morbidity and
mortality from accidents and injuries.
25The central
Figure 2 Deaths delayed or
averted in the counterfactual
scenario varying percentages of
non-drinkers. The percentage of
non-drinkers was allowed to vary
between 0% and 100% of the total
population using England 2006 as
the baseline. The median
consumption of alcohol among
those drinking was held constant.
Figure 1 Deaths delayed or
averted in the counterfactual
scenario varying median
consumption of alcohol in drinkers.
The median consumption of
alcohol among drinkers was
allowed to vary from 0 to 24 g/day
using England 2006 as the
baseline. The percentage of non-
drinkers in the population was held
constant.
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Modelling optimal alcohol consumption levels for chronic disease preventionrecommendation from the results of this paperdthat
a target consumption level for England should be half
a unit per daydis, however, likely to be consistent with
low levels of risk for accidents and injuries. Heavy
irregular drinking has also been linked with increased
risk of CVD.
21 Guidance to the public about avoiding
heavy drinking sessions remains a very important
component of any public health guidance around
alcohol consumption. In addition, it is not possible to
include wholly alcohol-attributable conditions (eg,
mental and behavioural disorders due to alcohol use) in
the model.
The PRIME-Alcohol model is necessarily limited by the
availability of robust meta-analytic estimates of RR for
mortality and estimates generated are limited by the
quality of available evidence to parameterise the model.
The observational studies included in the meta-analyses
used to parameterise the PRIME-Alcohol model used
self-report of alcohol consumption, which may result in
an under-estimate of actual alcohol consumption,
22 and
results from observational studies cannot account for
within-individual variability in alcohol consumption.
Although there is a strong body of epidemiological
evidence over many years linking moderate alcohol
consumption with lower rates of CVD,
23e25 concerns
remain about possible residual confounding or other
methodological explanations for the observed
relationship.
25 26
Sex-speciﬁc estimates of RR at varying levels of alcohol
consumption were available only for hypertensive disease
and liver cirrhosis, and no age-speciﬁc estimates were
available, which limits the speciﬁcity of the counterfac-
tual scenarios analysed by the model. Furthermore,
results are based on the assumption of a steady-state
relationship between alcohol consumption levels and RR
of disease, while in reality, there is a lag time between
changes in alcohol consumption levels and mortality
risk. For some conditions included in the model, RR
estimates from appropriate meta-analysis were available
only for incidence of the disease, rather than mortality;
however, this is unlikely to signiﬁcantly impact on the
accuracy of estimates unless there was an additional
effect of alcohol consumption on case-fatality ratios for
the included conditions.
The predicted results, in terms of increases or
decreases in mortality expected at varying levels of
alcohol consumption are entirely dependent upon the
baseline population inputsdparticularly current alcohol
consumption levels and current levels of mortality from
the included chronic diseases (which will reﬂect among
other things, prevalence of other risk factors and both
treatment- and prevention-related healthcare variables).
The level of alcohol consumption associated with the
most favourable predicted change from existing
mortality levels may vary substantially between popula-
tions. It is also important to emphasise that the results
indicate predicted impacts on mortality only and do not
account for alcohol-related chronic disease morbidity,
which has a signiﬁcant impact on population health and
the health system.
This study is an important addition to the current
debate around alcohol consumption and public health,
combining and balancing risk and protective factors to
identify an optimal population level of alcohol
consumption associated with reduced levels of chronic
disease mortality. This is in contrast to recent publica-
tions focusing on the associations between alcohol and
speciﬁc conditions. For example, Schutze and
colleagues
9 concluded that their analyses of the associ-
ation between alcohol intake and cancer ‘support
current political efforts to reduce or to abstain from
alcohol consumption to reduce the incidence of cancer’.
In contrast, a recent systematic review of the impact of
alcohol on CVD concluded that ‘alcohol, in moderation,
may have overall health beneﬁts that outweigh the risks
in selected subsets of patients’.
11 Only by systematically
combining the effects of alcohol on all alcohol-related
conditions can appropriate public health messages be
developed. The results of this modelling exercise
contribute to further building all the evidence required
to make such an assessment.
The ﬁndings from this paper are consistent with those
from a meta-analysis of alcohol consumption and total
mortality,
27 which also found lowest mortality risk
around 5 g of alcohol per day and a Europe-wide study
28
that found minimum risk for alcohol-attributable deaths
at 10 g/day or less (the smallest consumption category
included in that study). A strength of our modelling
approach, in comparison to cross-sectional studies or
ﬁxed meta-analyses of total mortality, is that it can
account for differences between populations in under-
lying risk of various chronic diseases and can therefore
be used to predict population-speciﬁc curves of poten-
tial changes in chronic disease mortality for interna-
tional comparisons. Future work should therefore
produce comparable results for international popula-
tions with varying current levels of exposure and
outcomes. Furthermore, there is a signiﬁcant interac-
tion between alcohol consumption and other lifestyle
risk factors for chronic disease mortality, and future
work should seek to integrate alcohol consumption with
risk behaviours such as poor nutrition, low physical
activity and smoking to compare the relative contribu-
tions that improvements in these risk factors, both
independently and in combination, could have on
population health.
CONCLUSIONS
Our modelling suggests that the optimum level of
reduced chronic disease mortality in England would be
achieved at an average alcohol consumption level of
around 5 g/day, which should be taken into account in
the formulation of health guidance. It is likely that
government recommendations would need to be set at
a much lower level than the current ‘low-risk’ drinking
guidelines in order to achieve this level.
Nichols M, Scarborough P, Allender S, et al. BMJ Open 2012;2:e000957. doi:10.1136/bmjopen-2012-000957 7
Modelling optimal alcohol consumption levels for chronic disease preventionContributors PS conceived the study and developed the methods, with support
from MN, SA and MR. MN conducted literature searches to inform the model
and PS and MN built the model and conducted analysis. All authors
contributed to interpretation of the results. MN prepared the initial draft and led
the preparation of the manuscript. All authors were involved in drafting and
reviewing the manuscript. MN and PS act as guarantors for the manuscript.
Funding PS, SA and MR are supported by the British Heart Foundation (grant
numbers PPC/Jul05/5b and PPC/JAN05/6biii). MN and SA were partially
supported by the Australian Government Department of Health and Ageing.
Competing interests None.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement The PRIME-Alcohol model is available for use upon
request from PS (peter.scarborough@dph.ox.ac.uk).
REFERENCES
1. Corrao G, Bagnardi V, Zambon A, et al. A meta-analysis of alcohol
consumption and the risk of 15 diseases. Prev Med 2004;38:613e19.
2. Rehm J, Baliunas D, Borges GL, et al. The relation between different
dimensions of alcohol consumption and burden of disease: an
overview. Addiction 2010;105:817e43.
3. Danaei G, Ding EL, Mozaffarian D, et al. The preventable causes of
death in the United States: comparative risk assessment of dietary,
lifestyle, and metabolic risk factors. PLoS Med 2009;6:e1000058.
4. Scarborough P, Bhatnagar P, Wickramasinghe KK, et al. The
economic burden of ill health due to diet, physical inactivity, smoking,
alcohol and obesity in the UK: an update to 2006e07 NHS costs. J
Public Health (Oxf) 2011;33:527e35.
5. Taylor B, Irving HM, Kanteres F, et al. The more you drink, the harder
you fall: a systematic review and meta-analysis of how acute alcohol
consumption and injury or collision risk increase together. Drug
Alcohol Depend 2010;110:108e16.
6. Cherpitel CJ. Alcohol and injuries: a review of international emergency
room studies since 1995. Drug Alcohol Rev 2007;26:201e14.
7. Borges G, Cherpitel C, Orozco R, et al. Multicentre study of acute
alcohol use and non-fatal injuries: data from the WHO collaborative
study on alcohol and injuries. Bull World Health Organ 2006;84:453e60.
8. WCRF/AICR. World Cancer Research Fund and American Institute for
Cancer Research. Food, Nutrition, Physical Activity, and the Prevention
of Cancer: a Global Perspective. Washington, DC: AICR, 2007.
9. Schutze M, Boeing H, Pischon T, et al. Alcohol attributable burden of
incidence of cancer in eight European countries based on results from
prospective cohort study. BMJ 2011;342:d1584.
10. Winstanley MH, Pratt IS, Chapman K, et al. Alcohol and cancer:
a position statement from Cancer Council Australia. Med J Aust
2011;194:479e82.
11. Ronksley PE, Brien SE, Turner BJ, et al. Association of alcohol
consumption with selected cardiovascular disease outcomes:
a systematic review and meta-analysis. BMJ 2011;342:d671.
12. Koppes LL, Dekker JM, Hendriks HF, et al. Moderate alcohol
consumption lowers the risk of type 2 diabetes: a meta-analysis
of prospective observational studies. Diabetes Care
2005;28:719e25.
13. Baliunas DO, Taylor BJ, Irving H, et al. Alcohol as a risk factor for type
2 diabetes: a systematic review and meta-analysis. Diabetes Care
2009;32:2123e32.
14. Department of Health, Home Ofﬁce (United Kingdom). Safe.
Sensible. Social. The Next Steps in the National Alcohol Strategy.
London: Department of Health and Home Ofﬁce, 2007.
15. World Health Organization. Global Health Risks: Mortality and Burden
of Disease Attributable to Selected Major Risks. Geneva: World
Health Organization, 2009.
16. Taylor B, Irving HM, Baliunas D, et al. Alcohol and hypertension:
gender differences in dose-response relationships determined
through systematic review and meta-analysis. Addiction
2009;104:1981e90.
17. Samokhvalov AV, Irving H, Mohapatra S, et al. Alcohol consumption,
unprovoked seizures, and epilepsy: a systematic review and meta-
analysis. Epilepsia 2010;51:1177e84.
18. Rehm J, Taylor B, Mohapatra S, et al. Alcohol as a risk factor for liver
cirrhosis: a systematic review and meta-analysis. Drug Alcohol Rev
2010;29:437e45.
19. Ofﬁce for National Statistics. Overview Report. General Household
Survey, 2006. London, UK: Ofﬁce for National Statistics, 2008.
20. Goddard E. Smoking and drinking among adults 2006. General
Household Survey 2006. London, UK: Ofﬁce for National Statistics, 2008.
21. Bagnardi V, Zatonski W, Scotti L, et al. Does drinking pattern modify
the effect of alcohol on the risk of coronary heart disease? Evidence
from a meta-analysis. J Epidemiol Community Health
2008;62:615e19.
22. Koppes LL, Twisk JW, Snel J, et al. Concurrent validity of alcohol
consumption measurement in a ‘healthy’ population; quantity-
frequency questionnaire v. dietary history interview. Br J Nutr
2002;88:427e34.
23. Thun MJ, Peto R, Lopez AD, et al. Alcohol consumption and mortality
among middle-aged and elderly U.S. adults. N Engl J Med
1997;337:1705e14.
24. Wannamethee SG, Shaper AG. Lifelong teetotallers, ex-drinkers
and drinkers: mortality and the incidence of major coronary heart
disease events in middle-aged British men. Int J Epidemiol
1997;26:523e31.
25. Howie EK, Sui X, Lee DC, et al. Alcohol consumption and risk of all-
cause and cardiovascular disease mortality in men. J Aging Res
2011;2011:805062.
26. Di Castelnuovo A, Costanzo S, Donati MB, et al. Prevention of
cardiovascular risk by moderate alcohol consumption: epidemiologic
evidence and plausible mechanisms. Intern Emerg Med
2010;5:291e7.
27. Di Castelnuovo A, Costanzo S, Bagnardi V, et al. Alcohol dosing and
total mortality in men and women: an updated meta-analysis of 34
prospective studies. Arch Intern Med 2006;166:2437e45.
28. Rehm J, Zatonksi W, Taylor B, et al. Epidemiology and alcohol policy
in Europe. Addiction 2011;106(Suppl 1):11e19.
PAGE fraction trail=7.75
8 Nichols M, Scarborough P, Allender S, et al. BMJ Open 2012;2:e000957. doi:10.1136/bmjopen-2012-000957
Modelling optimal alcohol consumption levels for chronic disease prevention